Geovax Labs Reports a 2010 4TH QTR Net Loss of $478,784 (Financial Report‪)‬

GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, has announced its financial results for the fourth quarter and year ended December 31, 2010. GeoVax reported a net loss of $478,784 for the fourth quarter ended December 31, 2010, as compared to a net loss of $843,275 for the comparable period in 2009. For the full year of 2010, the company reported a net loss of $2,747,328 as compared to a net loss of $3,284,252 in 2009. Grant revenues were $5,185,257 and $3,668,195 for the years ended December 31, 2010 and 2009, respectively. As of December 31, 2010, the company reported cash balances totaling $1,079,087. Summarized financial information is attached. Further information concerning the company's financial position and results of operations are included in its Annual Report on Form 10-K, expected to be filed with the Securities and Exchange Commission before March 31, 2011. Highlights of the company's scientific and clinical progress during 2010 are as follows: